Portal de investigação
Inervação simpática e mecanismos adrenérgicos locais na regulação funcional da córnea
Dados básicos
- Código:
- Estudo Clínico Académico
- Protocolo:
- Estudo Clínico Académico
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2019
- Ano de conclusão:
Objectivos do projeto
Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
In vitro and in vivo anti-epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2-related self-limited epilepsy
Monni, L; (...); Fidzinski, P
Article. 10.1111/bph.15689. 2022
In vitro Species Different Metabolism and CYP Phenotyping of Zamicastast
Loureiro, Ana; (...); Soares-da-Silva, Patricio
Meeting Abstract. 10.1096/fasebj.2020.34.s1.05520. 2020
A Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Zamicastat, in Healthy Male Volunteers
Magalhaes, L.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
A Randomized, Double-Blind, Placebo-Controlled and Open-Label, Active-Controlled, 4-Period Crossover Trial to Evaluate the Effect of Zamicastat on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions
Gama, H.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Absorption, metabolism and excretion of opicapone in human healthy volunteers
Loureiro, AI; (...); Soares-da-Silva, P
Article. 10.1111/bcp.15383. 2022
ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
ADOPTION Study: Status Update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
An updated safety review of eslicarbazepine acetate in pregnancy after 11 years of post-marketing experience
Vieira, M.; (...); Gama, H.
Meeting Abstract. 2021
Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate
Rogin, J; (...); Grinnell, T
Article. 10.1111/ane.13218. 2020
Antagonistic modulation of SIK1 and SIK2 isoforms in high blood pressure and cardiac hypertrophy triggered by high-salt intake
Pires, NM, Igreja, B, Soares-da-Silva, P
Article. 10.1080/10641963.2021.1896728. 2021
Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients
Araujo, Ana M.; (...); Soares-da-Silva, Patricio
Article. 10.1186/s12871-019-0856-x. 2019
Boosting caffeic acid performance as antioxidant and monoamine oxidase B/catechol-O-methyltransferase inhibitor
Chavarria, D; (...); Borges, M.
Article. 10.1016/j.ejmech.2022.114740. 2022
Burden of Care-Partners of People with Parkinson's Disease: Findings from Parkinson's Disease Real-World Impact Assessment (PRISM) Study
Tolosa, E.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Burden of Care-Partners of People with Parkinson's disease: Findings from Parkinson's disease Real-World Impact Assessment (PRISM) Study
Tolosa, E.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Cardiometabolic and Inflammatory Benefits of Sympathetic Down-Regulation with Zamicastat in Aged Spontaneously Hypertensive Rats
Igreja, Bruno; (...); Soares-da-Silva, Patricio
Article. 10.1021/acsptsci.9b00039. 2019
Cellular and Mitochondrial Toxicity of Tolcapone, Entacapone, and New Nitrocatechol Derivatives
Pinto, M; (...); Borges, F
Article. 10.1021/acsptsci.4c00124. 2024
Complex effects of eslicarbazepine on inhibitory micro networks in chronic experimental epilepsy
Schmidt, S; (...); Beck, H
Article. 10.1111/epi.16808. 2021
Change in OFF-/ON-Time After Switching from Double-Blind Entacapone or Placebo to Open-Label Opicapone in Patients who Ended the 1-Year BIPARK-I Extension Study on Opicapone 50mg
Poewe, W.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Changes in Activities of Daily Living and Motor Function in Patients Switching from Entacapone or Placebo to Opicapone who Ended BIPARK-I Extension on Opicapone 50mg
Tolosa, E.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Characterization of the pattern of daily motor fluctuations in Parkinson's disease patients based on home diaries
Hauser, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Design of a double-blind, randomized, phase II trial in the prevention of epilepsy in stroke: anti-epileptogenic effects of eslicarbazepine acetate
Koepp, Matthias; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2021
Dopamine-beta-hydroxylase Short Interfering Nucleic Acid Overcomes the Short-term Efficacy of Timolol and Bimatoprost in Noradrenergic Overactivated Glaucomatous Eye
Carneiro, C.; (...); Soares-da-Silva, P.
Meeting Abstract. 2023
Drug-Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady-State Conditions in Healthy Subjects
Fonseca, Marlene; (...); Soares-da-Silva, Patricio
Article. 10.1002/jcph.2486. 2024
Drug-drug interaction study between zamicastat and furosemide in healthy subjects
Santos, Ana; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1183/13993003.congress-2021.PA1930. 2021
Drug-drug interaction study between zamicastat and sildenafil in healthy subjects
Santos, Ana; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1183/13993003.congress-2020.1458. 2020
Drug-Drug Interaction Study Between Zamicastat and Treprostinil in Healthy Subjects
Magalhaes, L.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
DRUG-DRUG INTERACTION STUDY BETWEEN ZAMICASTAT AND WARFARIN IN HEALTHY SUBJECTS
Magalhaes, Luis; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.chest.2020.08.1928. 2020
Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson's disease patients
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson's disease patients with motor fluctuations
Videnovic, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Effect of opicapone and entacapone on levodopa short duration response
LeWitt, P.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Effect of opicapone in Parkinson's disease patients with `early' motor fluctuations: Parkinson's disease questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience
Rocha, F.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1150. 2019
Effect of opicapone in Parkinson's disease patients with `early' motor fluctuations: Parkinson's Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience
Rocha, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Effect of Toll-like receptor-2, -4, -5, -7, and NOD2stimulation on potassium channel conductance in intestinal epithelial cells (vol 323, pg G410, 2022)
Cosme, D., Soares-da-Silva, P., Magro, F.
Correction. 10.1152/ajpgi.00139.2023_COR. 2023
Effect of Toll-like receptor-2,-4,-5,-7, and NOD2 stimulation on potassium channel conductance in intestinal epithelial cells
Cosme, Dina, Soares-da-Silva, Patricio, Magro, Fernando
Article. 10.1152/ajpgi.00139.2022. 2022
Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double-blind, randomized, placebo-controlled study in healthy subjects
Fonseca, M; (...); Soares-da-Silva, P
Article. 10.1111/bcp.16167. 2024
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
Moura, Eduardo; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1183/13993003.congress-2020.3560. 2020
Effectiveness and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients with Motor Fluctuations: the OPTIPARK Study
Reichmann, Heinz; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2020
Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study
Reichmann, H; (...); Soares-da-Silva, P
Article. 10.1186/s40035-020-00187-1. 2020
Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study (vol 9, 9, 2020)
Reichmann, Heinz; (...); Soares-da-Silva, Patricio
Correction. 10.1186/s40035-020-00193-3. 2020
Effectiveness of Opicapone in Parkinson's according to baseline use of dopamine agonists: the real-world OPTIPARK study
Jost, W.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of Opicapone in Parkinson's according to baseline use of entacapone: the real-world OPTIPARK study
Jost, W.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of Opicapone in Parkinson's according to baseline use of MAO-B inhibitors & DA: real-world OPTIPARK study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of Opicapone in Parkinson's according to baseline use of safinamide: the real-world OPTIPARK study
Pavese, N.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study
Jost, Wolfgang; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119432. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study
Jost, W.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of entacapone: Findings from the real-world OPTIPARK study
Jost, Wolfgang; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119439. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of monoamine-oxidase-b inhibitors and dopamine agonists: The real-world OPTIPARK study
Reichmann, Heinz; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119433. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study
Pavese, N.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of safinamide: Findings from the real-world OPTIPARK study
Pavese, Nicola; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119427. 2021
Effects of Opicapone on Sleep in Patients with Parkinson's Disease and Motor Fluctuations
Hauser, R.; (...); Klepitskaya, O.
Meeting Abstract. 2021
Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial
Kirkham, F; (...); Soares-da-Silva, P
Article. 10.1016/j.yebeh.2020.106962. 2020
Efficacy and safety of opicapone in Parkinson's disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK-I and II
Ebersbach, G.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Efficacy and Safety of Opicapone in Parkinson's Disease Patients According to Duration of Motor Fluctuations: Post-Hoc Analysis of BIPARK-I and II
Ebersbach, G.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naive Parkinson's disease patients recently diagnosed with motor fluctuations
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
EFFICACY AND SAFETY/TOLERABILITY OF OPICAPONE IN CATECHOL-O-METHYLTRANSFERASE INHIBITOR-NAIVE PARKINSON'S DISEASE PATIENTS RECENTLY DIAGNOSED WITH MOTOR FLUCTUATIONS
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Efficacy of opicapone according to different levodopa daily frequencies in Parkinson's patients with motor fluctuations
Ebersbach, G.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations
Ebersbach, G.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations
Ebersbach, Georg; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119446. 2021
Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations
Antonini, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations
Antonini, Angelo; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119450. 2021
Efficacy of opicapone according to levodopa's duration of use in Parkinson's disease patients with motor fluctuations
Antonini, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Efficacy of opicapone at different levodopa regimens up to a threshold of 600 mg/day levodopa in Parkinson's disease patients with motor fluctuations
Lewitt, Peter; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119445. 2021
Efficacy of Opicapone at Different Levodopa Regimens up to a Threshold of 600mg/Day Levodopa in Parkinson's Disease Patients with Motor Fluctuations
LeWitt, Peter A.; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2020
Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naive Parkinson's disease patients recently diagnosed with motor fluctuations: A post-hoc conservative analysis
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson's disease patients with motor fluctuations
Antonini, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
EFFICACY OF OPICAPONE IN DIFFERENT TREATMENT REGIMENS IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS
Antonini, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Efficacy of opicapone in Parkinson's disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1153. 2019
Efficacy of opicapone in Parkinson's disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Efficacy of opicapone in Parkinson's disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Efficacy of opicapone in Parkinson's disease patients according to baseline presence of dyskinesia: A post-hoc analysis from combined BIPARK-I and II
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1152. 2019
Efficacy of opicapone in Parkinson's disease patients according to baseline rasagiline use: A post-hoc analysis from combined BIPARK-I and II
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1154. 2019
Efficacy of opicapone in Parkinson's disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Efficacy of opicapone in Parkinson's disease patients with `early' motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience
Rocha, F.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1151. 2019
Efficacy of Opicapone in Patients with Parkinson's Disease with Levodopa Dose Reduction: a Pooled Post-Hoc Analysis of BIPARK-I and II
Rascol, O.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
EFFICACY OF OPICAPONE VERSUS ENTACAPONE IN CATECHOL-O-METHYLTRANSFERASE INHIBITOR-NAIVE PARKINSON'S DISEASE PATIENTS RECENTLY DIAGNOSED WITH MOTOR FLUCTUATIONS: A POST-HOC CONSERVATIVE ANALYSIS
Ferreira, J. J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
EFFICACY/SAFETY OF OPICAPONE IN PARKINSON'S DISEASE PATIENTS ACCORDING TO DURATION OF MOTOR FLUCTUATIONS: POST-HOC ANALYSIS OF BIPARK-I AND II
Ebersbach, G.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Gene silencing of LAT1 and ASCT2 Transporters via Short Interfering Nucleic Acid Therapies upon Human Colon Cancer HCT-116 Cell Xenografts
Carneiro, C.; (...); Soares-da-Silva, P.
Meeting Abstract. 2023
Impact of 3-month earlier versus later initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson's disease and motor fluctuations
Carroll, Camille; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119447. 2021
Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson's disease and motor fluctuations
Carroll, C.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Impact of 3-month early versus postponed initiation of opicapone vs entacapone in Parkinson's levodopa-treated patients
Carroll, C.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Impulse Control Behaviours in People with Parkinson's Disease: Findings from the Parkinson's Disease Real-World Impact Assessment (PRISM) Study
Antonini, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Impulse Control Behaviours in People with Parkinson's Disease: Findings from the Parkinson's Disease Real-World Impact Assessment (PRISM) Study
Antonini, A.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Inactivation Mechanism of the Fatty Acid Amide Hydrolase Inhibitor BIA 10-2474
Cerqueira, Nuno M. F. S. A.; (...); Palma, P. Nuno
Article. 10.1002/cbic.202200166. 2022
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data
Ikedo, F.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1167. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline disease severity: Post-hoc analysis from double-blind combined BIPARK-I and II data
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1170. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1168. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
Ikedo, F.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline mao-b inhibitors use: Post-hoc analysis from double-blind combined BIPARK-I and II data
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1171. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to gender: post-hoc analysis from double-blind combined BIPARK-I and II data
Ikedo, F.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to gender: Post-hoc analysis from double-blind combined BIPARK-I and II data
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1169. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to race: Post-hoc analysis from double-blind combined BIPARK-I and II data
Costa, R.; (...); Savic, N.
Meeting Abstract. 10.1016/j.jns.2019.10.1172. 2019
Incidence of treatment-emergent adverse events in Parkinson's disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Influence of baseline OFF-time in the efficacy response of Parkinson's disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Santos, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
INFLUENCE OF BASELINE OFF-TIME ON OPICAPONE EFFICACY IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS
Korlipara, P.; (...); Soares-Da-Silva, P.
Meeting Abstract. 10.1136/jnnp-2019-ABN-2.134. 2019
Influence of demographic characteristics in the efficacy response of Parkinson's disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Santos, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Influence of demographic characteristics on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Mohamed, B.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Influence of demographic characteristics on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
Mohamed, Biju; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119431. 2021
Influence of demographic features in Opicapone effectiveness in Parkinson's patients: the real-world OPTIPARK study
Mohamed, B.; (...); Soares-da-silva, P.
Meeting Abstract. 2021
Influence of disease duration in the efficacy response of Parkinson's disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Gama, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Influence of disease duration in the Opicapone effectiveness in Parkinson's patients: real-world OPTIPARK study
Warnecke, T.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Influence of disease duration on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
Warnecke, Tobias; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119440. 2021
Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Gama, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Influence of disease severity in the efficacy response of Parkinson's disease patients with motor fluctuations: Post-hoc analysis from combined BIPARK-I and II
Santos, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1192. 2019
Influence of levodopa daily dose in Opicapone effectiveness in Parkinson's: the real-world OPTIPARK study
Carroll, C.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Influence of levodopa daily dose on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
Carrolla, Camille; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119426. 2021
Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson's disease patients: post-hoc analysis from combined BIPARK-I and II
Santos, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Influence of onset of motor fluctuations in the Opicapone effectiveness in Parkinson's: real-world OPTIPARK study
Jost, W.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Jost, W.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study
Jost, Wolfgang; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119425. 2021
Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson's Disease Patients with Motor Fluctuations
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Liver says no: the ongoing search for safe catechol O-methyltransferase inhibitors to replace tolcapone
Silva, TB; (...); Soares da Silva, P
Review. 10.1016/j.drudis.2020.07.015. 2020
Long-term effect of Toll-like receptor-2,-4,-5,-7 and NOD2 stimulation on Na plus , K plus -ATPase activity and expression in intestinal epithelial cells
Cosme, D, soares-da-silva, p, Magro, F
Article. 10.1152/ajpcell.00208.2022. 2023
Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study
Trinka, E; (...); Soares-da-Silva, P
Article. 10.1111/epi.16666. 2020
Long-term efficacy of opicapone in reducing ON-time troublesome dyskinesia in patients reporting troublesome dyskinesia
Stocchi, F.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Long-term efficacy of opicapone in the reduction of on-time with troublesome dyskinesia in Parkinson's disease patients with motor fluctuations and reporting troublesome dyskinesia
Stocchi, Fabrizio; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119442. 2021
Long-term Efficacy of Opicapone in the Reduction of ON-time with Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations and Reporting Troublesome Dyskinesia
Stocchi, Fabrizio; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2021
Long-Term Efficacy of Opicapone in the Reduction of On-Time with Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations and Reporting Troublesome Dyskinesia
Stocchi, Fabrizio; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2020
Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping
Loureiro, I, Ana; (...); Soares-da-Silva, Patricio
Article. 10.1002/prp2.891. 2022
Metabolism and disposition of zamicastat in rats.
Araújo F; (...); Loureiro AI
Article. 10.1080/00498254.2024.2411993. 2024
Mexazolam main metabolite chlorordiazepam affinity to different GABAa a3 receptor subtypes. A comparison with Alprazolam
Fernandes, H; (...); Soares da Silva, P
Meeting Abstract. 10.1016/j.euroneuro.2019.09.234. 2019
Non-clinical toxicology evaluation of BIA 10-2474
Hayes, AW; (...); soares-da-silva, p
Review. 10.1080/10408444.2020.1867821. 2021
OCEAN Study in Parkinson's Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone
Chaudhuri, K.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Off-Time and Sleep in Patients with Parkinson's Disease and Motor Fluctuations
Hauser, Robert A.; (...); Klepitskaya, Olga
Meeting Abstract. 2021
Once-Daily Opicapone Increases ON-Time in Patients with Parkinson's Disease and Motor Fluctuations: Results from Two Randomized, Double-Blind, Placebo-Controlled Studies
LeWitt, Peter; (...); Liang, Grace S.
Meeting Abstract. 2019
ONSET OF DRUG-RELATED ADVERSE EVENTS IN PARKINSON'S DISEASE PATIENTS TREATED WITH OPICAPONE IN CLINICAL PRACTICE: OPTIPARK POST-HOC ANALYSIS
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Onset of Drug-Related Adverse Events in Parkinson's Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Onset of Drug-Related Adverse Events in Parkinson's Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
Lees, Andrew J.; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2020
Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson's Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone analysis of health economic costs in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study
Lees, Andrew; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119441. 2021
Opicapone Analysis of Health Economic Costs in Parkinson's UK: findings from the OPTIPARK Study
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials
Hauser, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
OPICAPONE AS FIRST-LINE ADJUNCTIVE LEVODOPA TREATMENT IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS: BIPARK-I AND II COMBINED POST-HOC ANALYSIS
Ferreira, J. J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson's Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson's Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Ferreira, J. J.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Opicapone effect at different levodopa regimens up to 600 mg/d threshold in Parkinson's patients and motor fluctuations
LeWitt, P.; (...); Klepitskaya, O.
Meeting Abstract. 2021
Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys
Bonifacio, Maria Joao, Sousa, Filipa, Soares-da-Silva, Patricio
Article. 10.1016/j.ejphar.2020.173742. 2021
Opicapone in clinical practice in Parkinson's disease German patients with motor fluctuations: Findings from the OPTIPARK study
Reichmann, Heinz; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119429. 2021
Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone in clinical practice in Parkinson's disease patients with motor fluctuations and complications of therapy at baseline: Findings from the OPTIPARK study
Reichmann, Heinz; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119451. 2021
Opicapone in Clinical Practice in Parkinson's Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Opicapone in Clinical Practice in Parkinson's disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Reichmann, H.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
OPICAPONE IN CLINICAL PRACTICE IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS: FINDINGS FROM THE OPTIPARK STUDY
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Opicapone in Clinical Practice in Parkinson's Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone in clinical practice in Parkinson's disease UK patients with motor fluctuations: Findings from the OPTIPARK study
Lees, Andrew; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119428. 2021
Opicapone in Clinical Practice in Parkinson's UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Lees, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone in German Parkinson's disease patients with motor fluctuations: Results on WOQ-9, QoL and non-motor symptoms.
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Opicapone in Parkinson's Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone in Parkinson's German Patients with Motor Fluctuations: findings from the OPTIPARK Study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone in Parkinson's patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study
Reichmann, H.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone OASIS study in Parkinson's: design of an open-label, single-arm, pilot trial
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data
Rocha, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data
Rocha, F.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.379. 2019
Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations
Reichmann, H; (...); Soares-da-Silva, P
Article. 10.1159/000523771. 2022
OPICAPONE'S ADDED BENEFIT AS A FIRST-LINE ADJUNCTIVE THERAPY TO LEVODOPA AND WHEN USED PROMPTLY FOR MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE
Ebersbach, G.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Opicapone's added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson's disease: a post-hoc analysis of BIPARK-I and II
Ebersbach, G.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Over-blending effect of lubricants on capsules manufacturing: a simple and fast wettability technique to predict batch dissolution performance
Barrocas, P.; (...); Vasconcelos, T.
Article. 10.1080/10837450.2023.2196332. 2023
Overcoming short term efficacy of timolol an bimatoprost in noradrenergic overactivated glaucomatous eye with chemically modified short interference nucleic acids targeting dopamine-beta-hydroxylase
Carneiro, Catarina; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2023
Patient characteristics, treatment patterns and disease burden in people with Parkinson's disease: insights from the Parkinson's disease real-world impact assessment (PRISM) study
Foltynie, T.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Patient Characteristics, Treatment Patterns and Disease Burden in People with Parkinson's Disease: Insights from the Parkinson's Disease Real-World Impact Assessment (PRISM) Study
Foltynie, T.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
PHASE 1 STUDY TO INVESTIGATE THE EFFECT OF P-GLYCOPROTEIN TRANSPORTER INHIBITION MEDIATED BY CARVEDILOL ON THE PHARMACOKINETICS OF ZAMICASTAT
Magalhaes, Luis; (...); Soares-da-Silva, Patricio
Meeting Abstract. 10.1016/j.chest.2021.07.2015. 2021
Population Pharmacokinetic-Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS)
Araújo, AM; (...); Falcao, A
Article. 10.1002/jcph.1560. 2020
Population pharmacokinetic-pharmacodynamic modeling for propofol anesthesia guided by the Bispectral Index (BIS) (vol 60, pg 617, 2020)
Araujo, A. M.; (...); Falcao, A.
Correction. 10.1002/jcph.1764. 2020
Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474
Bonifácio, MJ; (...); Soares-da-Silva, P
Article. 10.1111/bph.14973. 2020
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone
Jenner, P; (...); Soares-da-Silva, P
Review. 10.1080/14737175.2021.1968298. 2021
Regulatory safety pharmacology evaluation of BIA 10-2474
Hayes, AW; (...); soares-da-silva, p
Article. 10.1016/j.vascn.2020.106677. 2020
Safety and Tolerability of Once-Daily Opicapone in Patients with Parkinson's Disease and Motor Fluctuations: Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled Studies
Kremens, Daniel; (...); Liang, Grace S.
Meeting Abstract. 2019
Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience
Magalhaes, LM; (...); Soares-da-Silva, P
Article. 10.1007/s40264-021-01097-5. 2021
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers
Rocha, JF; (...); Soares-da-Silva, P
Article. 10.1002/cpt.2290. 2022
Salt-inducible kinases: new players in pulmonary arterial hypertension?
Antonio, Tatiana; (...); Gomes, Pedro
Review. 10.1016/j.tips.2022.06.008. 2022
SLEEP PATTERNS AND ``OFF''-TIME IN PATIENTS WITH PARKINSON'S DISEASE AND MOTOR FLUCTUATIONS
Hauser, Robert; (...); Klepitskaya, Olga
Meeting Abstract. 2022
Status Update of EPSILON: a Phase III, Randomised, Placebo-Controlled Study of Opicapone in Early Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Status Update of EPSILON: a Phase III, Randomised, PlaceboControlled Study of Opicapone in Early Parkinson's Disease
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2022
Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients
Ferreira, Joaquim; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119438. 2021
Study Design to Assess the Effect of Opicapone on Levodopa PK at Different Levodopa-Optimized Treatment Regimens in Parkinson's Disease Patients
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
Study-Design to Assess the Effect of Opicapone on Levodopa PK at Different Levodopa-Optimized Treatment Regimens
Ferreira, J.; (...); Soares-da-silva, P.
Meeting Abstract. 2021
Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson's Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II
Antonini, A.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
Super-responders to opicapone adjunct treatment to levodopa in parkinson's disease patients with motor fluctuations: combined post-hoc analysis of BIPARK-I and II
Antonini, A.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2020
Switching entacapone `non-responders' to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2019
Switching entacapone `non-responders' to open-label opicapone: Change in absolute off-time following the 1-year extension BIPARK-I study
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1207. 2019
Switching from double-blind entacapone or placebo to open-label opicapone: change in OFF-/ON-time from patients who ended the 1-year BIPARK-I extension on opicapone 50 mg
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 10.1016/j.jns.2019.10.1208. 2019
SWITCHING FROM DOUBLE-BLIND ENTACAPONE OR PLACEBO TO OPEN-LABEL OPICAPONE: NMSS RESULTS (1-YEAR EXTENSION BIPARK-I STUDY)
Fabregues, O.; (...); Soares-Da-Silva, P.
Meeting Abstract. 10.1136/jnnp-2019-ABN-2.133. 2019
Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results from patients who ended 1-year BIPARK-I extension on opicapone 50 mg
Rocha, F.; (...); Savic, N.
Meeting Abstract. 10.1016/j.jns.2019.10.1249. 2019
Sympathetic Down-Regulation With Etamicastat Ameliorates High Blood Pressure in a Model of Drug-Resistant Hypertension
Igreja, Bruno; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2019
Sympathetic Down-regulation With Zamicastat Reduces Arrhythmogenicity in Isolated Hearts From Rats With Pulmonary
Pires, Nuno; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2020
The ADOPTION (eArly levoDopa with Opicapone in Parkinson's paTients wIth motOr fluctuatioNs) study in Parkinson's disease: design and rationale of a randomized prospective, open-label exploratory trial
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
The design of a multicentre, double-blind, randomized, placebo-controlled, Phase II trial in the prevention of epilepsy in stroke patients at high risk of unprovoked seizures: Anti-epileptogenic effects of eslicarbazepine acetate
Koepp, M.; (...); Soares-Da-Silva, P.
Meeting Abstract. 2022
The Dopamine Beta-Hydroxylase Inhibitor Zamicastat Improves Survival in the Rat Monocrotaline Model of Pulmonary Arterial Hypertension
Bonifacio, M.; (...); Soares-da-Silva, P.
Meeting Abstract. 2020
The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson's disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study
Ferreira, J.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
The OASIS (OpicApone in Sleep dISorder) study in Parkinson's disease: design and rationale of an open-label, single-arm, pilot trial
Costa, R.; (...); Soares-da-Silva, P.
Meeting Abstract. 2021
The oasis (opicapone in sleep disorder) study in Parkinson's disease: Design and rationale of an open-label, single-arm, pilot trial
Costa, Raquel; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1016/j.jns.2021.119430. 2021
The role of salt-inducible kinases on the modulation of renal and intestinal Na+,K+-ATPase activity during short- and long-term high-salt intake
Ant, T; (...); Soares da Silva, P.
Article. 10.1016/j.ejphar.2021.174153. 2021
Voltage-clamp evidence of GABA(A) receptor subunit-specific effects: pharmacodynamic fingerprint of chlornordiazepam, the major active metabolite of mexazolam, as compared to alprazolam, bromazepam, and zolpidem
Fernandes, H; (...); Soares-da-Silva, P
Article. 10.1007/s43440-022-00411-x. 2022
Wistar: Han Rats Are Not All the Same. An RNAseq Approach to Access Supplier Differences in the Monocrotaline Model of Pulmonary Arterial Hypertension (PAH)
Batalha, Vania; (...); Soares-da-Silva, Patricio
Meeting Abstract. 2019
Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension
Pires, Nuno; (...); Soares-Da-Silva, Patricio
Meeting Abstract. 10.1183/13993003.congress-2020.1483. 2020
Zamicastat is a noncompetitive Dopamine-ß-hydroxylase inhibitor that modulates sympathetic nervous system activity
Bonifacio, Maria-Joao; (...); Soares-da-Silva, Patricia
Meeting Abstract. 10.1096/fasebj.2020.34.s1.05359. 2020
